Orforglipron

Orforglipron is an oral GLP-1 receptor agonist currently in clinical development for obesity and type 2 diabetes management. Users typically run the substance at a daily dose of 15 mg, though reported usage spans a wide range from 500 µg to 45 mg. While the compound is studied for weight loss and glycemic control, the current evidence base for off-label applications remains thin, with most exploratory indications lacking published results. Reports of side effects are minimal, with only isolated mentions of sleep and dream changes, while common concerns like nausea or injection-site reactions have not been a consistent theme in community reports.

Half-life~36 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.84.01.42.83.25.0

Research Evidence

Evidence shape

Orforglipron possesses high-tier clinical evidence, supported by 48 registered trials that establish its efficacy for obesity and type 2 diabetes. The research base is robust, featuring 19 trials with posted results and seven blinded studies that demonstrate significant weight loss and HbA1c reduction. While the primary indications are well-supported by large-scale data, the broader clinical landscape remains exploratory, with eight additional indications currently backed by only thin or single-trial evidence. This concentration of results in metabolic health highlights a significant gap between its primary applications and its long-tail experimental use.

Depthhow much
50 registered trials
32 completed · 24 with posted results · 18 recruiting / active · combined n=3130
Breadthhow many areas
13 indications mapped
4 with results · 8 thin / exploratory · 1 animal-only · 7 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
10 blinded with results · AE rows aggregated from 23 trials · 14 linked publications on registered trials
Breadth and depth56 rows captured
Human
direct clinical signal
50
Animal
translational support
3
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Orforglipron side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Disguisedalpha
US
60526 mg
$149.99
$0.002/mg
2
Swiss Chems
International
540 mg×90
$198.95
$0.37/mg
3
stratelabs.is
IS
360 mg×60
$160.00
$0.44/mg
4
Happypeptides
US
270 mg×90
$165.00
$0.61/mg
5
PureHealth Peptides
--
6 mg
$129.00
$21.5/mg
6
Pure Rawz
--
6 mg
$200.98
$33.5/mg

price offers can be sorted by column

1-6 of 7

Orforglipron dosing & protocol

How Orforglipron is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 32
Typical dose
2 mg1 mg – 3 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 13 reported doses · darker = more
Frequency
daily
Route
oral

In research trials, Orforglipron was taken orally at 1–3 mg once daily, with 2 mg being the typical dose; no specific cycling regimen was reported.

32 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
10 mg
20 mg
30 mg
40 mg
50 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 82
Typical dose
15 mg500 µg – 45 mg
typical
0
10 mg
20 mg
30 mg
40 mg
50 mg
distribution of 88 reported doses · darker = more
Frequency
unspecified
Route
oral

Most community reports cite an oral dose around 15 mg, with a range from 500 µg to 45 mg, and do not specify a regular frequency or cycling pattern.

82 sources

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including FOUNDAYO. Discontinue if pancreatitis is suspected.
  • • Severe Gastrointestinal Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. FOUNDAYO is not recommended in patients with severe gastroparesis.
  • • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
  • • Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemi…
  • • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If suspected, advise the patient to promptly seek medical attention and discontinue FOUNDAYO.
  • • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression.
  • • Acute Gallbladder Disease : Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated.
  • • Pulmonary Aspiration During General Anesthesia and Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…
Contraindications
  • • FOUNDAYO is contraindicated in
  • • patients with: A personal or family history of MTC or in
  • • patients with MEN 2 [see Warnings and Precautions (5.1) ] . Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema,…
  • • patients with MEN 2 Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO
Drug interactions
  • • Inhibitors: The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 inhibitors that also inhibit OATP1B. (7.1) CYP3A4
  • • Inducers: Avoid concomitant use with strong CYP3A4 inducers. Monitor FOUNDAYO effectiveness and escalate dosage as needed when used concomitantly with moderate CYP3A4 inducers. (7.1)
  • • Simvastatin: Do not exceed simvastatin 20 mg once daily when used concomitantly with FOUNDAYO. (7.2) FOUNDAYO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.3)

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604CagrilintideLiraglutideExenatideTesamorelinEloralintideMazdutideTesofensine